Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HMR code 24-001
- Development stage
- Phase 1
- Lead developer
- Nxera Pharma
01
Overview
HMR code 24-001 is a clinical trial protocol identifier for a Phase I clinical study sponsored by Nxera Pharma UK Limited (formerly Sosei Heptares) in healthy human volunteers. The trial is designed as a randomized, placebo-controlled crossover MRI interventional study utilizing a caffeine challenge to evaluate neuroimaging metrics. Because the trial is registered under a deferred publication scheme, the specific identity, chemical structure, and mechanism of action of the investigational drug being evaluated remain confidential and have not been publicly disclosed.
Beyond the preview
Go deeper on HMR code 24-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HMR code 24-001.